Open AccessUsage of ursodeoxycholic acid in cardiology (literature review and own data)
Author(s) -
О. М. Радченко,
L. M. Strilchuk,
Z. M. Kit,
I. B. Zhakun,
O. O. Sorokopud,
M. O. Kondratyuk
Publication year - 2019
Publication title -
lìkarsʹka sprava/lìkarsʹka sprava
Language(s) - English
Resource type - Journals
eISSN - 2706-8803
pISSN - 1019-5297
DOI - 10.31640/jvd.1-2.2019(5
Subject(s) - ursodeoxycholic acid , medicine , cholic acid , enterohepatic circulation , bile acid , ezetimibe , atorvastatin , gastroenterology , cholesterol , endocrinology , pharmacology
Ursodeoxycholic acid (UDCA) influences bile formation and excretion. Apart from that, UDCA has some pleiotropic effects, which can be a basis for usage of this drug for treatment of cardiovascular diseases. We held a scientific literature review in РubМed database and domestic literature sources according to key words “ursodeoxуcholic acid”, “chenodeoxуcholic acid”, “enterohepatic circulation”, “bile acids”. It was revealed that UDCA has a wide spectrum of action because of its cytoprotective, anti-apoptotic, anti-inflammatory, anti-oxidative and immune-modulating effects, which are of particular importance in cardiology. Some authors propose to use UDCA in patients with ischemic heart disease, especially in case of comorbid metabolic syndrome and nonalcoholic steatohepatitis. We determined the level of leptin in the blood by immunoenzyme method in 43 patients with arterial hypertension before and after a month of outpatient treatment by atorvastatin or ursodeoxycholic. It was shown that both drugs led to significant decrease of blood serum atherogenic influence due to decrease of total cholesterol and cholesterol of low-density lipoproteins (more expressed in the statin group) and due to decrease of previously increased leptin level (more expressed in the UDCA group). Investigation of drug influence on adipocytokinessynthesis in patients with cardiovascular diseases is perspective in terms of its correction possibilities.